Evidence map›Paper›PMID 41817317›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2026

Ionizing Radiation Enhances Prognostically Significant Cellular Immunity Programs in the Brain Metastasis Microenvironment.

Kazutaka Fukumura, Peixin Jiang, Debra Nana Yeboa, Akshara Singareeka Raghavendra, Maria A Gubbiotti, Clark R Andersen, Sherise D Ferguson, Dzifa Yawa Duose, Yujin Kudo, Banu Arun and 3 more

Abstract read
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kazutaka Fukumura *Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-5975-4120
Peixin Jiang *Department of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0009-0005-8033-1639
Debra Nana Yeboa *Department of Radiation Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-2901-7477
Akshara Singareeka RaghavendraDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6425-4400
Maria A GubbiottiDepartment of Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-2246-7958
Clark R AndersenDepartment of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-1846-9117
Sherise D FergusonDepartment of Neurosurgery, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6344-0615
Dzifa Yawa DuoseDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-6763-9736
Yujin KudoDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-3187-9970
Banu ArunDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0002-5475-8509
Alexandre ReubenDepartment of Thoracic/Head and Neck Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4510-0382
Jason T HuseDepartment of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0003-4514-0640
Nuhad K IbrahimDepartment of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, Texas.ORCID 0000-0001-8660-243X

Funding

Tropism Enhanced Oncolytic Adenovirus for the Treatment of Brain TumorsP50CA127001 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Juan Fueyo, FREDERICK F LANG · 2008 to 2026
$41.2M
Brockman Medical Grant FoundationNational Cancer Institute (NCI) P50CA127001NCI NIH HHS P50 CA127001Richard Spencer Memorial FundRobert Wood Johnson Foundation (RWJF)Sheila Wynne Research Fund
6 · The paper itself

Abstract

purposeBrain metastasis (BM) is a deadly complication of systemic malignancy that has been associated with defective cellular immunity. We sought to characterize the foundational elements and clinical relevance of BM-associated immunosuppression using integrated molecular profiling in primary patient material. EXPERIMENTAL

designRetrospective patient tissue cohorts of breast (n = 153) and lung (n = 153) cancer BM were stratified by histopathologic scoring of tumor-infiltrating lymphocytes (TIL) and clinical outcome, with a large subset of breast cancer samples further analyzed by T-cell receptor sequencing (TCR-seq) and RNA sequencing (RNA-seq). An ongoing clinical trial comparing pre- and postoperative stereotactic radiosurgery (SRS)/stereotactic radiotherapy (SRT) in BM management was then leveraged to dissect radiation-induced immune responses by TCR- and RNA-seq.

resultsPatients with high-grade histopathologic TIL infiltration and enriched TCR diversity demonstrated favorable prognoses in breast and lung cancer BM. Moreover, SRS/SRT treatment enhanced TCR diversity in the BM microenvironment, along with signatures of antigen processing and presentation. Finally, integrated analysis demonstrated that IR seemed to reactivate immune microenvironmental signatures normally suppressed in BM and upregulate immune signaling pathways correlated with favorable outcomes in patients with breast cancer BM.

conclusionsHigh TCR diversity in BM is associated with improved prognosis and highlights therapeutically tractable targets within the immune microenvironment. Moreover, we show in a prospective clinical trial that IR enhances T-cell-mediated immune responses, upregulating antigen presentation and enhancing TCR diversity in BM. These results argue for increased therapeutic investigations of radiation-induced immunomodulatory effects in BM, potentially in association with immune checkpoint inhibition.

Indexed as

Brain NeoplasmsBreast NeoplasmsImmunity, CellularLung NeoplasmsRadiation, IonizingTumor MicroenvironmentFemaleHumansLymphocytes, Tumor-InfiltratingPrognosisRadiosurgeryReceptors, Antigen, T-CellRetrospective StudiesReceptors, Antigen, T-Cell

Identifiers

PMID41817317
PMCPMC13223553

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.